Ovary removal could be risky for young women

	Tweet

Women who undergo removal of both ovaries before the age of 45 years have an increased risk of early mortality if they do not receive estrogen replacement treatment up to the age of 45 years, according to research conducted at the Mayo Clinic in Rochester, Minnesota.

Dr. Walter A. Rocca and his team followed women who underwent ovary removal, either for a benign condition or as preventative measure, before age 45 and before the onset of menopause.

The study included 1091 women who had both ovaries removed, 1274 who underwent removal of one ovary, and 2383 women from the general population. They were followed for an average of 30 years.

Overall, mortality rates were no higher among women who had both ovaries removed than among women in the other two groups, the investigators report in The Lancet Oncology medical journal. However, the risk of death was almost doubled for women who underwent double ovary removal for preventative reasons before age 45 and who did not receive estrogen replacement up to age 45.

Rocca’s group points out that, as a result of the widely publicized Women’s Health Initiative trial, hormone replacement therapy has been sharply curtailed among women of any age.

They propose that the Women’s Health Initiative trial findings, which linked hormone replacement among postmenopausal women to increased risks of breast cancer and stroke, may not apply to women with menopause before 50 years of age—so recommendations regarding hormone therapy for this group should be reconsidered.

SOURCE: Lancet Oncology, October 2006.

RELATED STORIES:
First baby is born after a new technique -Ovarian transplantation   Study Provides Clues to Prevent Spread of Ovarian Cancer   Ovarian Cancer Screening Not Catching Early Disease   BRCA2 genetic mutation associated with improved survival and chemotherapy response in ovarian cancer   Angiogenesis Linked to Poor Survival in Patients with Rare Type of Ovarian Cancer   Low-dose Pill reduces ovarian cancer risk   Analgesic drugs don’t reduce ovarian cancer risk   Ovarian cancer subtypes are different diseases: Implications for biomarker studies   Commercial Sale of Ovarian Cancer Test Deemed Illegal by FDA   ‘Clumping’ Protein Linked to Return of Ovarian Cancer   Body cavity drugs cut ovarian cancer death risk   Ovarian Cancer Study Gets Aid   Researchers identify genes that may help in ovarian cancer diagnosis and prognosis   New Treatment Implications for Ovarian Cancer Unveiled   OHSU Primate Center’s Ovarian Cancer Finding May be a “Win-Win” for At-Risk Women Who Wish to Have a Family   Ovarian Cancer: the Not-so-silent Killer   Drinking Tea Associated with Lower Risk of Ovarian Cancer   Genetic factors implicated in survival gap for breast, ovarian or prostate cancer   Ovarian cancer screening approach may be flawed   New platinum-phosphate compounds kill ovarian cancer cells   More study needed on vitamin D-ovarian cancer link   Physical activity does not ward off ovarian cancer

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]